Format

Send to:

Choose Destination
See comment in PubMed Commons below
Allergy. 2016 Mar 10. doi: 10.1111/all.12880. [Epub ahead of print]

Paving the way of systems biology and precision medicine in allergic diseases: The MeDALL success story.

Author information

  • 1University Hospital, Montpellier, France.
  • 2MACVIA-LR, Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon, European Innovation Partnership on Active and Healthy Ageing Reference Site, France.
  • 3INSERM, VIMA: Ageing and chronic diseases. Epidemiological and public health approaches, U1168, Paris, and UVSQ, UMR-S 1168, Université Versailles St-Quentin-en-Yvelines, France.
  • 4ISGLoBAL, Centre for Research in Environmental Epidemiology CREAL, Barcelona, Spain.
  • 5IMIM Hospital del Mar Research Institute, Barcelona, Spain.
  • 6CIBER Epidemiología y Salud Pública CIBERESP, Barcelona, Spain.
  • 7Universitat Pompeu Fabra UPF, Barcelona, Spain.
  • 8Swiss Institute of Allergy and Asthma Research SIAF, University of Zurich, Davos, Switzerland.
  • 9European Institute for Systems Biology and Medicine,CNRS-ENS-UCBL, Université de Lyon, France.
  • 10Institute of Social Medicine, Epidemiology and Health Economics, Charité - Universitätsmedizin Berlin, Berlin, and Institute for Clinical Epidemiology and Biometry, University of Wuerzburg, Germany.
  • 11Department of Public health and health products, Paris Descartes University-Sorbonne Paris Cité, EA 4064 and Paris municipal Department of social action, childhood, and health, Paris, France.
  • 12University of Groningen, University Medical Center Groningen, Department of Pulmonary Medicine and Tuberculosis, GRIAC Research institute, Groningen, the Netherlands.
  • 13Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.
  • 14Sachs' Children and Youth Hospital, Södersjukhuset, Stockholm and Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
  • 15UMR Inserm U 1027 and Université de Toulouse III Paul Sabatier, Toulouse, France.
  • 16Skin and Allergy Hospital, Helsinki University Hospital, Helsinki, Finland.
  • 17VIB Inflammation Research Center, Ghent University, Ghent, Belgium.
  • 18Oslo University Hospital, Department of Paediatrics, Oslo, and University of Oslo, Faculty of Medicine, Institute of Clinical Medicine, Oslo, Norway.
  • 19Department of Pediatric Pulmonology and Pediatric Allergology, Beatrix Children's Hospital, GRIAC Research Institute, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
  • 20Allergy-Centre-Charité at the Department of Dermatology, Charité - Universitätsmedizin Berlin, Secretary General of the Global Allergy and Asthma European Network, GA2LEN, Berlin, Germany.
  • 21EPAR U707 INSERM, Paris and EPAR UMR-S UPMC, Paris VI, Paris, France.
  • 22Onmedic Networks, Barcelona, Spain.
  • 23Department of Dermatology and Allergy Centre, Odense University Hospital, Odense, Denmark.
  • 24EFA European Federation of Allergy and Airways Diseases Patients' Associations, Brussels, Belgium.
  • 25Department of Epidemiology, Regional Health Service Lazio Region, Rome, Italy.
  • 26Institute of Epidemiology I, German Research Centre for Environmental Health, Helmholtz Zentrum München, Neuherberg, Germany.
  • 27Department of Immunology, Rheumatology and Allergy, Medical University of Lodz, Poland.
  • 28Biomax Informatics AG, Munich, Germany.
  • 29Centre for Occupational and Environmental Medicine, Stockholm County Council, Stockholm, Sweden.
  • 30Julius Center of Health Sciences and Primary Care, University Medical Center Utrecht, University of Utrecht, Utrecht, the Netherlands.
  • 31Bradford Institute for Health Research, Bradford Royal Infirmary, Bradford, UK.
  • 32Clinical Immunology and Allergy Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, and Astrid Lindgren Children's Hospital, Department of Pediatric Pulmonology and Allergy, Karolinska University Hospital, Stockholm, Sweden.
  • 33St John's Institute of Dermatology, King's College London, London, UK.
  • 34Instititute for Risk Assessment Sciences, Utrecht University, Utrecht, The Netherlands.
  • 35Institute of Social Medicine, Epidemiology and Health Economics, Charité - Universitätsmedizin, Berlin, Germany.
  • 36Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Stockholm, Sweden.
  • 37Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, and Department of ENT diseases, Karolinska University Hospital, Stockholm, Sweden.
  • 38Inserm Transfert, Paris, France.
  • 39Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
  • 40ENT Dept, Ghent University Hospital, Gent, Belgium.
  • 41Environment and Health Area, Centre for Public Health Research CSISP;CIBERESP, Department of Nursing, University of Valencia, Valencia, Spain.
  • 42Research Institute, Department of Pediatrics, Marien-Hospital, Wesel, Germany.
  • 43Department of Paediatrics, Oslo University Hospital and University of Oslo, Oslo, Norway.
  • 44Department of Social Medicine, Faculty of Medicine, University of Crete, PO Box 2208, Heraklion, 7 1003, Crete, Greece.
  • 45Department of Respiratory Diseases, Montpellier University Hospital, France.
  • 46Department of Medicine and Public Health, Alma Mater Studiorum - University of Bologna, via San Giacomo 12, 40126, Bologna, Italy.
  • 47Allergology department, Centre de l'Asthme et des Allergies. Hôpital d'Enfants Armand-Trousseau APHP; Sorbonne Universités, UPMC Univ Paris 06, UMR_S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Equipe EPAR, F-75013, Paris, France.
  • 48Division of Paediatric Gastroenterology and Hepatology, Ludwig Maximilians University of Munich, Germany.
  • 49Department for Pediatric Pneumology and Immunology, Charité Medical University, Berlin, Germany.
  • 50Department of Environmental Immunology/Core Facility Studies, Helmholtz Centre for Environmental Research - UFZ, Leipzig, Germany.
  • 51Chemotargets SL and Chemogenomics Laboratory, GRIB Unit, IMIM-Hospital del Mar and University Pompeu Fabra, Barcelona, Catalonia, Spain.
  • 52Département de pédiatrie, CHU de Grenoble, BP 217, 38043, Grenoble cedex 9, France.
  • 53Inserm, U823, Grenoble.
  • 54ib-salut, Area de Salut de Menorca, Spain.

Abstract

MeDALL Mechanisms of the Development of ALLergy; EU FP7-CP-IP; Project No: 261357; 20 10 -2015 proposed an innovative approach to develop early indicators for the prediction, diagnosis, prevention and targets for therapy. MeDALL linked epidemiological, clinical and basic research using a stepwise, large-scale and integrative approach: precisely phenotyped children followed in 14 birth cohorts spread across Europe were combined with systems biology omics, IgE measurement using micro-arrays and environmental data. Multimorbidity in the same child is more common than expected by chance alone, suggesting that these diseases share causal mechanisms irrespective of IgE sensitisation. IgE sensitisation should be considered differently in mono and polysensitized individuals. Allergic multimorbidities and IgE polysensitization are often associated with the persistence or severity of allergic diseases. Environmental exposures are relevant for the development of allergy-related diseases. To complement the population-based studies in children, MeDALL included mechanistic experimental animal studies and in vitro studies in humans. The integration of multimorbidities and polysensitization has resulted in a new classification framework of allergic diseases that could help to improve the understanding of genetic and epigenetic mechanisms of allergy as well as to better manage allergic diseases. Ethics and gender were considered. MeDALL had translational activities deployed within the EU agenda. This article is protected by copyright. All rights reserved.

This article is protected by copyright. All rights reserved.

KEYWORDS:

Asthma; IgE; multimorbidity; polysensitization; rhinitis

PMID:
26970340
[PubMed - as supplied by publisher]

Publication Types

Publication Types

PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley
    Loading ...
    Write to the Help Desk